BTK and pemphigus: While BTK inhibitors have demonstrated efficacy in B cell malignancies and are under investigation for several autoimmune and immune-mediated dermatological diseases (e.g., pemphigus, chronic spontaneous urticaria, systemic lupus erythematosus), no published clinical trials or case series have evaluated their use in LP [49,50,51,52].